Drug Profile
Tecarfarin - Cadrenal Therapeutics
Alternative Names: ATI-5000; ATI-5923Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator ARYx Therapeutics
- Developer Cadrenal Therapeutics; Espero BioPharma; Lee's Pharmaceutical
- Class Anticoagulants; Antithrombotics; Small molecules; Vascular disorder therapies
- Mechanism of Action Vitamin K epoxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Thromboembolism; Thrombosis
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in China (PO)
- 09 Mar 2023 Cadrenal Therapeutics plans the ACTOR-AF phase III trial for Thromboembolism (Prevention) (PO)
- 23 Jan 2023 Tecarfarin - Espero BioPharma receives Fast Track designation for Thromboembolism [PO,od] (Prevention) in USA